Context is a Critical for Psychoactive Drug Effects

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2023 Nov 24

PMID 37999869

Authors

Kyle T Greenway

Affiliations

Soon will be listed here.

Citing Articles

The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample.

Calder A, Qualls C, Hasler G, Elmiger D, Strassman R Biol Psychiatry Glob Open Sci. 2025; 5(2):100436.

PMID: 39926700 PMC: 11804565. DOI: 10.1016/j.bpsgos.2024.100436.

References

Carhart-Harris R, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I . Psychedelics and the essential importance of context. J Psychopharmacol. 2018; 32(7):725-731. DOI: 10.1177/0269881118754710. View

Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N . The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology (Berl). 2018; 235(2):505-519. PMC: 5893695. DOI: 10.1007/s00213-017-4820-5. View

Johnson M, Richards W, Griffiths R . Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008; 22(6):603-20. PMC: 3056407. DOI: 10.1177/0269881108093587. View

Kaelen M, Barrett F, Roseman L, Lorenz R, Family N, Bolstridge M . LSD enhances the emotional response to music. Psychopharmacology (Berl). 2015; 232(19):3607-14. DOI: 10.1007/s00213-015-4014-y. View

Barrett F, Preller K, Herdener M, Janata P, Vollenweider F . Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music. Cereb Cortex. 2017; 28(11):3939-3950. PMC: 6887693. DOI: 10.1093/cercor/bhx257. View

Adamska I, Finc K . Effect of LSD and music on the time-varying brain dynamics. Psychopharmacology (Berl). 2023; 240(7):1601-1614. PMC: 10272181. DOI: 10.1007/s00213-023-06394-8. View

Friesen P . Psychosis and psychedelics: Historical entanglements and contemporary contrasts. Transcult Psychiatry. 2022; 59(5):592-609. PMC: 9660273. DOI: 10.1177/13634615221129116. View

HOCH P . Remarks on LSD and mescaline. J Nerv Ment Dis. 1957; 125(3):442-4. DOI: 10.1097/00005053-195707000-00018. View

Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R . Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. J Psychopharmacol. 2019; 33(9):1076-1087. DOI: 10.1177/0269881119855974. View

10.

Griffiths R, Johnson M, Richards W, Richards B, McCann U, Jesse R . Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011; 218(4):649-65. PMC: 3308357. DOI: 10.1007/s00213-011-2358-5. View

11.

Hartogsohn I . Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. 2016; 30(12):1259-1267. DOI: 10.1177/0269881116677852. View

12.

Garel N, Drury J, Thibault Levesque J, Goyette N, Lehmann A, Looper K . The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Front Psychiatry. 2023; 14:1268832. PMC: 10546328. DOI: 10.3389/fpsyt.2023.1268832. View

13.

Bremner J, Krystal J, Putnam F, Southwick S, Marmar C, Charney D . Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998; 11(1):125-36. DOI: 10.1023/A:1024465317902. View

14.

van Schalkwyk G, Wilkinson S, Davidson L, Silverman W, Sanacora G . Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. J Affect Disord. 2017; 227:11-16. PMC: 6248324. DOI: 10.1016/j.jad.2017.09.023. View

15.

Ballard E, Zarate Jr C . The role of dissociation in ketamine's antidepressant effects. Nat Commun. 2020; 11(1):6431. PMC: 7755908. DOI: 10.1038/s41467-020-20190-4. View

16.

Dakwar E, Anerella C, Hart C, Levin F, Mathew S, Nunes E . Therapeutic infusions of ketamine: do the psychoactive effects matter?. Drug Alcohol Depend. 2014; 136:153-7. PMC: 4091719. DOI: 10.1016/j.drugalcdep.2013.12.019. View

17.

Studerus E, Gamma A, Vollenweider F . Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One. 2010; 5(8):e12412. PMC: 2930851. DOI: 10.1371/journal.pone.0012412. View

18.

Sanches R, Osorio F, Dos Santos R, Macedo L, Maia-de-Oliveira J, Wichert-Ana L . Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. J Clin Psychopharmacol. 2015; 36(1):77-81. DOI: 10.1097/JCP.0000000000000436. View

19.

Feduccia A, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer M, Doblin R . Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Front Psychiatry. 2019; 10:650. PMC: 6751381. DOI: 10.3389/fpsyt.2019.00650. View

20.

Holze F, Vizeli P, Muller F, Ley L, Duerig R, Varghese N . Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. 2019; 45(3):462-471. PMC: 6969135. DOI: 10.1038/s41386-019-0569-3. View